학술논문
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401
Document Type
Article
Author
Dummer, R.; Corrie, P.; Gutzmer, R.; Meniawy, T.M.; Del Vecchio, M.; Lebbé, C.; Guida, M.; Dutriaux, C.; Dreno, B.; Meyer, N.; Ferrucci, P.F.; Dalle, S.; Khattak, M.A.; Grob, J.-J.; Briscoe, K.; Larkin, J.; Mansard, S.; Lesimple, T.; Guidoboni, M.; Sabatini, S.; Richtig, E.; Herbst, R.; Lobo, M.; Askelson, M.; Ascierto, P.A.; Maio, M.
Source
In: Journal of Clinical Oncology . (Journal of Clinical Oncology, 10 August 2023, 41(23):3917-3929)
Subject
Language
English
ISSN
15277755
0732183X
0732183X